Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Rhea-AI Summary

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that its CDMO subsidiary, Scinai Biopharma Services, has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration, reporting to CEO Amir Reichman. Kuratz brings over 30 years of leadership in supply chain and operations across pharmaceutical, biotechnology, medical-device and industrial companies, including senior roles at Kamada, Gamida Cell, OdysightAI, Elite PepsiCo-Frito-Lay and EnvyHer.

In his new role, he oversees supply chain and operational support functions such as procurement and contracting, warehousing, logistics, inventory management, budgeting and cost control, bookkeeping administration, and IT and business systems, including ERP, CRM, quality-management platforms and cybersecurity. According to the company, this appointment supports integration and scale-up following the first-quarter 2026 acquisition of Recipharm Israel, which added a Yavne site complementing the Jerusalem biologics facility and expanded Scinai’s CDMO capacity and technical capabilities.

Market Context

The active F-3 is a resale registration for selling shareholders, while the company receives proceed...

Analysis

The active F-3 is a resale registration for selling shareholders, while the company receives proceeds only if warrants are exercised. For this appointment, execution across the two-site platform remains the key operational consideration and shelf-related supply is a risk.

Key Figures

Appointment date: Aug. 10, 2026 Leadership experience: More than 30 years CDMO sites: Two sites +1 more

4 metrics

Appointment date Aug. 10, 2026 Head of Supply Chain and Business Process Administration appointment

Leadership experience More than 30 years Senior leadership, supply chain and operational experience

CDMO sites Two sites Jerusalem and Yavne operations

Acquisition timing First quarter of 2026 Recipharm Israel acquisition and CDMO platform expansion

Historical Context

5 past events · Latest: Jun 10 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 10	Q1 earnings report	Negative	-7.7%	Revenue declined and operating loss widened despite bargain purchase gain-driven net income.
May 20	Leadership appointment	Positive	-6.0%	Yavne CDMO facility appointed a new site head with biotechnology leadership experience.
May 15	Strategic roundtable	Neutral	+0.2%	Company led a dermatology summit discussion on oral therapies and biologics.
Apr 24	Private placement	Negative	+61.6%	Company announced $2.61 million financing with ADSs and warrant inducement.
Apr 06	Corporate reorganization	Positive	+1.7%	Company established a dedicated CDMO subsidiary after acquiring the Yavne site.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed: the May 20 operational appointment fell 6.02%, while the April 6 reorganization rose 1.67%.

Key Terms

cdmo, gmp, erp, crm, +1 more

5 terms

cdmo technical

"a contract development and manufacturing organization (CDMO)"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

gmp regulatory

"GMP API manufacturing"

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

erp technical

"enterprise platforms including ERP, CRM and quality-management systems"

ERP, or Enterprise Resource Planning, is a comprehensive software system that helps organizations manage and integrate core business processes such as finance, supply chain, and human resources in one unified platform. For investors, ERP systems can indicate how efficiently a company operates; strong and well-integrated systems often suggest good management and potential for sustainable growth.

crm technical

"enterprise platforms including ERP, CRM and quality-management systems"

Customer relationship management (CRM) is the set of tools, practices and software companies use to track and manage interactions with customers and potential customers, like an organized digital address book combined with a sales coach. It matters to investors because effective CRM systems can boost sales, improve customer retention and lower marketing costs, which directly affects revenue growth and profit margins — key drivers of a company’s value.

sterile fill-and-finish medical

"aseptic manufacturing and sterile fill-and-finish capabilities"

A sterile fill-and-finish is the manufacturing step where a finished drug substance or vaccine is transferred into its final sterile containers (like vials, syringes, or cartridges), sealed, labeled, and prepared for distribution under strict cleanliness controls. Think of it like bottling a beverage in a completely germ-free room: it determines how quickly and safely doses can reach the market, affects production capacity, regulatory inspections, and the risk of costly contamination or delays.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.

JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eran Kuratz as Head of Supply Chain and Business Process Administration. Mr. Kuratz reports directly to Scinai Chief Executive Officer Amir Reichman.

Mr. Kuratz brings more than 30 years of senior leadership, supply chain and operational experience across the pharmaceutical, biotechnology, medical-device and industrial sectors. He has held senior positions at Kamada, Gamida Cell, OdysightAI, Elite PepsiCo-Frito-Lay and EnvyHer, including roles as CEO, Co-CEO, Director of Supply Chain and Director of Purchasing and Logistics. His experience spans global operations, procurement, logistics, warehousing, enterprise systems and strategic planning in highly regulated environments. Mr. Kuratz is a Practical Engineer in Industrial Engineering and Management from the Technological College of Be'er Sheva.

In his new role, Mr. Kuratz leads Scinai Biopharma Services' supply chain and key operational support functions, including procurement and contracting, warehousing and inventory management, logistics, budgeting and cost control, bookkeeping administration, and IT and business systems. He is also responsible for enterprise platforms including ERP, CRM and quality-management systems, cybersecurity, and the continuous improvement of cross-functional business processes across the organization.

Amir Reichman, Chief Executive Officer of Scinai, commented:

"Following the expansion of our CDMO platform and the integration of our Jerusalem and Yavne operations, we are increasingly focused on building the systems, processes and organizational infrastructure required to operate effectively at a larger scale. Eran brings extensive experience in supply chain management, operational leadership and enterprise systems, and his appointment creates clear ownership for a number of critical cross-functional processes across the organization. We believe his experience will help us strengthen coordination between our sites and functions, improve operational discipline and establish scalable processes to support the continued growth of our CDMO platform and the broader Scinai organization."

Scinai expanded its CDMO platform in the first quarter of 2026 through the acquisition of Recipharm Israel from Recipharm AB, adding a second development and manufacturing site in Yavne and significantly broadening both its capacity and technical capabilities. The Jerusalem site is centered on biologics process development and also provides aseptic manufacturing and sterile fill-and-finish capabilities for parenteral injectable products, including both biologics and small molecules. The Yavne site adds complementary capabilities in small-molecule API process development and synthesis, analytical-method development and GMP API manufacturing. Together, the two sites enable Scinai Biopharma Services to support customers across a broader range of development and manufacturing needs. The transaction was also accompanied by a strategic commercial collaboration agreement with Recipharm AB, a global CDMO, extending Scinai's commercial reach and access to international opportunities.

About Scinai Immunotherapeutics.

Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit: www.scinai.com

Company Contacts
Business Development | +972 8 930 2529 | bd@scinai.com 
Investor Relations – Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the expected contribution of Mr. Kuratz to the Company's operations; the Company's ability to strengthen and integrate its operational infrastructure, systems and business processes; coordination between its sites and functions; the scalability of its operations; continued development and growth of its CDMO platform; and advancement of its R&D activities.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks related to the Company's ability to execute its operational and strategic plans; successfully integrate and optimize acquired operations; expand its CDMO activities; attract and retain customers and qualified personnel; implement and maintain effective operational processes and information systems; advance its therapeutic development programs; secure sufficient financing or non-dilutive funding; regain and maintain compliance with the Nasdaq listing requirements; and general market, industry, regulatory, geopolitical and economic conditions. More detailed information regarding these and other risks and uncertainties is included in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-strengthens-cdmo-leadership-with-appointment-of-eran-kuratz-as-head-of-supply-chain-and-business-process-administration-302847061.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

Who is Eran Kuratz and what is his new role at Scinai (NASDAQ: SCNI)?

Eran Kuratz has been appointed Head of Supply Chain and Business Process Administration at Scinai Biopharma Services. According to Scinai, he brings over 30 years of senior supply chain and operational experience across pharma, biotech, medical-device and industrial sectors to support the CDMO’s growth.

What responsibilities will Eran Kuratz have at Scinai Biopharma Services CDMO?

Kuratz will lead supply chain and key operational support functions, including procurement, contracting, warehousing, inventory, logistics, budgeting and cost control. According to Scinai, he also oversees ERP, CRM, quality-management systems, cybersecurity and continuous improvement of cross-functional business processes across the organization.

How does the new supply chain appointment relate to Scinai’s CDMO expansion in 2026 (SCNI)?

Scinai states that Kuratz’s appointment supports integration and scale-up after expanding its CDMO platform via acquiring Recipharm Israel in Q1 2026. The company indicates his role is to help build scalable systems and processes across the Jerusalem and Yavne sites.

What capabilities do Scinai’s Jerusalem and Yavne CDMO sites provide for clients?

The Jerusalem site focuses on biologics process development and aseptic sterile fill-and-finish for parenteral injectables. According to Scinai, the Yavne site adds small-molecule API process development, synthesis, analytical-method development and GMP API manufacturing, broadening customer development and manufacturing options.

What is Scinai Biopharma Services and how is it related to Scinai Immunotherapeutics (SCNI)?

Scinai Biopharma Services is a wholly owned CDMO subsidiary of Scinai Immunotherapeutics. According to Scinai, it provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, complementing the parent company’s pipeline of innovative immunology therapies.

How might Scinai’s collaboration with Recipharm AB affect its CDMO business?

The Recipharm Israel acquisition was accompanied by a strategic commercial collaboration agreement with Recipharm AB. According to Scinai, this collaboration extends its commercial reach and access to international CDMO opportunities, leveraging Recipharm’s global position to support customer growth.